BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 4, 2026
Home » Authors » Jim Stommen

Jim Stommen

Articles

ARTICLES

The MDD Interview: Size, geographic fit are key in hospitals consolidation

Aug. 30, 2013
By Jim Stommen

The MDD Interview: Modulating risk seen as key in hospitals' merger mania

Aug. 22, 2013
By Jim Stommen

The MDD Interview: Browning: Regulating electronic interfaces is can of worms for FDA

Aug. 15, 2013
By Jim Stommen

Deals roundup: Medtronic says Cardiocom advances its push on services

Aug. 13, 2013
By Jim Stommen

The MDD Interview: Change is imminent as FDA, industry forge new relationship

Aug. 8, 2013
By Jim Stommen

The MDD Interview: Ongoing mentoring builds upon lessons of initial training for vets

Aug. 1, 2013
By Jim Stommen

The MDD Interview: Returning veterans are focus of 'jobs in med-tech' program

July 25, 2013
By Jim Stommen

The MDD Interview: Schain: Market opportunity for CampusMD is almost limitless

July 18, 2013
By Jim Stommen
Devin Schain is the co-founder and CEO of CampusMD (Bethesda, Maryland), a provider of telemedicine-based services. CampusMD is underwritten by HealthNation, a nationwide telehealth service with an independent network of licensed physicians across the U.S., providing participating students with 24/7 access to U.S.-based, licensed physicians via telephone, online video and secure e-mail. Schain has founded and led several companies in the education space, launching his first as an undergraduate at the University of Pennsylvania. Schain now heads CampusDirect, a portfolio company that includes CampusMD among its businesses.
Read More

The MDD Interview: CampusMD uses telemedicine to help fill college health gaps

July 11, 2013
By Jim Stommen
Devin Schain is the co-founder and CEO of CampusMD (Bethesda, Maryland), a provider of telemedicine-based services. CampusMD is underwritten by HealthNation, a nationwide telehealth service with an independent network of licensed physicians across the U.S., providing participating students with 24/7 access to U.S.-based, licensed physicians via telephone, online video and secure e-mail. Schain has founded and led several companies in the education space, launching his first as an undergraduate at the University of Pennsylvania. He now heads CampusDirect, a portfolio company that includes CampusMD among its businesses.
Read More

The MDD Interview: Presence of other players doesn't diminish opportunities in epilepsy

July 3, 2013
By Jim Stommen
View All Articles by Jim Stommen

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

    BioWorld Science
    Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
  • Glucagon-like peptide-1 receptor (GLP-1R) complex

    Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

    BioWorld
    A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing